4 news items
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
PCSA
28 Mar 24
discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
PCSA
25 Mar 24
expertise to efficiently design and conduct clinical trials that demonstrate a positive benefit/risk relationship. The Processa team has a track
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
PCSA
21 Feb 24
year for each drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
PCSA
14 Feb 24
, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit from
- Prev
- 1
- Next